Effect of Admilparant (BMS-986278), an oral LPA1 antagonist, on time to disease progression in patients with pulmonary fibrosis: a post hoc analysis of a randomized trial — Michael Kreuter (2025) | RDL Network
Effect of Admilparant (BMS-986278), an oral LPA1 antagonist, on time to disease progression in patients with pulmonary fibrosis: a post hoc analysis of a randomized trial
Chao Gao, Mariusz Tomaniak, Kuniaki Takahashi, Hideyuki Kawashima, Rutao Wang, Hironori Hara, Masafumi Ono, Gilles Montalescot, Scot Garg, Michael Haude, Ton Slagboom, Pascal Vranckx, Marco Valgimigli, Stephan Windecker, Robert-Jan van Geuns, Christian Hamm, Philippe Gabríel Steg, Yoshinobu Onuma, Dominick J. Angiolillo, Patrick W. Serruys
Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann‐Lii Cheng, Stephen L. Chan, Thomas Yau, Baek‐Yeol Ryoo, Jennifer J. Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna R. Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.